Company intelligence / Profile preview

Tune Therapeutics

Durham, North Carolina, United Statestunetx.com ↗

Ownership: Private
Employees: ~140
Development stage: Phase 1

Overview

The company’s lead candidate, Tune‑401 for chronic Hepatitis B virus infection, entered clinical trials in New Zealand and Hong Kong in late 2024. The approach uses the TEMPO platform to silence viral DNA without altering the host genome. Early results or detailed outcomes have not yet been reported publicly as of early/mid‑2025.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Epigenetic editing/epi-editing (epigenome modulation)Gene regulation/tuning (non-permanent, non-DNA-cutting)Lipid nanoparticle delivery
Industry: Biotech

Drug pipeline

2 assets

T-401

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Acuitas Therapeutics Inc. (provides lipid nanoparticle technology for drug delivery)

Beyond the preview

Go deeper on Tune Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tune Therapeutics.

Explore the full profile